Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment

<h4>Background</h4> <p>Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed l...

Full description

Bibliographic Details
Main Authors:	Sliz, E, Kettunen, J, Holmes, MV, Williams, CO, Boachie, C, Wanq, Q, Mänikkö, M, Sebert, S, Walters, R, Lin, K, Millwood, IY, Clarke, RJ, Li, L, Rankin, N, Welsh, P, Delles, C, Jukema, JW, Trompet, S, Ford, I, Perola, M, Salomaa, V, Järvelin, M-R, Chen, Z, Lawlor, DA, Ala-Korpela, M, Danesh, J, Smith, GD, Sattar, N, Butterworth, A, Würtz, P
Format:	Journal article
Published:	American Heart Association 2018

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment

Similar Items